Preliminary Scientific program

Thursday, February 6

13:30-16:45  Pre-meeting workshops

(See details in “Workshops Hands on” section:)

17:00-18:00  Satellite Symposium Fidia

18:15  Welcome from the World Scleroderma Foundation

18:30  Welcome from the Patron of the World Scleroderma Foundation
   The impact of scleroderma on a creative genius
   A. Klee (CH)

18:45-19:00  Welcome from the Patients' Representative
   The Patients' Perspective
   A Kennedy (CH), President of FESCA

19:00-19:40  Opening Lectures
   Two-years in Review-What’s new since Madrid: the Cutting Edge
   Chairpersons: C Black (UK), F Wollheim (S)

19:00  The clinical overview
   M Matucci Cerinic (I)

19:20  The basic and translational I overview
   J Varga (USA)
Friday, February 7

08:00-09:20  **Session 1 - Management and assessment of newly diagnosed SSc**  
Chairpersons: van Laar J (UK), N Damjanov (SR)

- What to do for a patient with newly diagnosed SSc?  
  - How to assess a patient with new onset of possible systemic sclerosis  
  - What are the standard of care tests in early SSc patient  
  - What are the baseline factors of poor prognosis in very early and early SSc  

**P Clements (USA)**

**Chairpersons: F Van den Hoogen (NL), S Johnsson (CAN)**

08:20  NEW EULAR/ACR CLASSIFICATION CRITERIA FOR SYSTEMIC SCLEROSIS IN CLINICAL PRACTICE  
*O Distler et al (CH)*

08:30  2013 CLASSIFICATION CRITERIA FOR SYSTEMIC SCLEROSIS AN AMERICAN COLLEGE OF RHEUMATOLOGY/EUROPEAN LEAGUE AGAINST RHEUMATISM COLLABORATIVE INITIATIVE  
*J Pope et al (CAN)*

08:40  PERFORMANCE OF THE OLD 1980 ACR AND THE NEW ACR-EULAR SYSTEMIC SCLEROSIS (SSC) CLASSIFICATION CRITERIA IN PATIENTS WITH LIMITED CUTANEOUS SSC  
*P Carreira et al (E)*

08:50  EARLY ACCRUAL OF ORGAN DAMAGE IN SCLERODERMA: RATIONALE FOR DERIVATION AND VALIDATION OF A DISEASE DAMAGE INDEX IN SYSTEMIC SCLEROSIS  
*T Tay et al (AUS)*

09:00  PERFORMANCE OF THE 2013 ACR/EULAR CLASSIFICATION CRITERIA FOR SYSTEMIC SCLEROSIS IN A SINGLE CENTER SETTING  
*R Dobrota et al (R)*

09:10  SSC INTRINSIC SUBSET CLASSIFICATION IN PATIENTS THAT DEMONSTRATE CLINICAL IMPROVEMENT DURING TREATMENT  
*M Whitfield et al (USA)*

09:20–10:10  **Session 2 – Miscellaneous and differential diagnosis of SSc**  
Chairpersons: U Walker (CH), R Silver (USA)

- How to differentiate SSc from scleroderma-like disorder?  
  - Criteria for very early and early diagnosis of SSc  
  - Differential diagnoses to be presented including IgG4 syndromes, Shulman, nephrogenic fibrosis, borreliosis  

**A Tyndall (CH)**

09:40  GENDER EFFECTS ON SYSTEMIC SCLEROSIS PHENOTYPE: A LONGITUDINAL EUSTAR STUDY BASED ON MORE THAN 10 000 PATIENTS  
*M Elhai et al (F)*
3

Continue Friday, February 7

09:50  Epidemiology of Cancer in Systemic Sclerosis. Systematic Review and Meta-Analysis of Cancer Incidence, Predictors and Mortality
        S Johnson et al (CAN)

10:00  Joint and Tendon Involvement Predict Severe Disease Progression in Systemic Sclerosis: A EUSTAR Prospective Study
        J Avouac et al (F)

10:10-10:30  Coffee break

10:30-11:00  Session 3 – The great debate
        Chairpersons: R Giacomelli (I), B Maurer (CH)

        The place of Corticosteroids in SSc
        T Medsger (USA) & J Seibold (USA)

11:00-12:00  Poster tours

        Clinical
        Poster tour 1 - Raynaud & Ulcers - V Riccieri (I)
        Poster tour 2 - Raynaud & Ulcers - E Rosato (I)
        Poster tour 3 - Pulmonary/Interstitial Lung Disease - I H Turner (D)
        Poster tour 4 – Pulmonary Arterial Hypertension - D Launay (F)
        Poster tour 5 – Cardiac - A Vacca (I)
        Poster tour 6 – Outcomes, quality of life, psychological & social - P Carreira (E)
        Poster tour 7 – Imaging - F Cozzi (I)
        Poster tour 8 – Therapy/Miscellaneous - A Sulli (I)
        Poster tour 9 – Musculoskeletal system & rehabilitation - P Ostojić (SRB)
        Poster tour 10 – Upper and Lower Gastrointestinal/nutrition - T Minier (H)
        Poster tour 11 – Pregnancy & sexual problems – L Saketkoo (USA)
        Poster tour 12 – Therapy - S Bellando-Randone (I)

        Basic
        Poster tour 13 – Pathogenesis - M Manetti (I)
        Poster tour 14 – Pathogenesis - GL Moroncini (I)
        Poster tour 15 – Pathogenesis - S Assassi (USA)

12:00-13:30  Satellite Symposium Actelion

13:30-14:30  Lunch

14:30-15:30  Satellite Symposium GSK
Continue Friday, February 7

15:30–16:30 Session 4 - An integrated approach to gastro-intestinal involvement
Chairpersons: A Herrick (UK), T Frech (USA)

15:30 GI: How to evaluate, diagnose and treat upper and lower GI involvement
U Mueller-Ladner (D)

15:50 New therapeutic approaches
C Murray (UK)

16:10 MORTALITY, RECURRENCE AND HOSPITAL COURSE OF PATIENTS WITH SYSTEMIC SCLEROSIS (SSC) RELATED ACUTE INTESTINAL PSEUDO-OBSTRUCTION
C Derk et al (USA)

16:20 PREVALENCE, CORRELATES AND OUTCOMES OF GASTRIC ANTRAL VASCULAR ECTASIA IN SYSTEMIC SCLEROSIS: A EUSTAR CASE-CONTROL STUDY
E Ghrenassia et al (F)

15:30–16:30 Session 5 – PARALLEL SESSION BASIC
Links to inflammation, immunity and vascular disease
Chairpersons: J Distler (D), D Abraham (UK)

15:30 Immunological mechanisms of fibrosis
T Wynn (USA)

15:50 PIGMENT EPITHELIUM DERIVED FACTOR SECRETED BY SSC FIBROBLASTS INHIBITS ANGIO AND VASCULOGENESIS IN VITRO
V Liakouli et al (I)

16:00 SCLERODERMA DERMAL FIBROBLASTS OVEREXPRESS VASCULAR ENDOTHELIAL GROWTH FACTOR DUE TO AUTOCRINE TRANSFORMING GROWTH FACTOR BETA SIGNALING
I Kajihara et al (JPN)

16:10 IL6 TRANS-SIGNALLING AND CCL2 CO-REGULATE FIBROBLAST DEPENDENT TRANS-ENDOTHELIAL MIGRATION OF MONONUCLEAR CELLS AND FIBROTIC RESPONSE IN SCLERODERMA.
R Alade et al (UK)

16:20 THE GLOBAL MICRNORNA PROFILE OF SKIN IN SYSTEMIC SCLEROSIS
G Salazar et al (USA)

16:30 THE PRESENCE OF A COLD TEMPERATURE SENSOR IN THE VASCULAR ENDOTHELIUM: ENHANCED EXPRESSION IN SSC SKIN AND ENDOTHELIAL CELLS DYSFUNCTION AFTER ACTIVATION
B Kahaleh et al (USA)

16:40–16:55 Coffee break
16:55–17:25 **Session 6 – Biologics and novel therapies in SSc**  
Chairpersons: R Simms (USA), C Beyer (D)

Use of biologics in SSc—indications and future perspective  
- An update on the use of biologics in SSc  
- Benefit/risk ratio of the main molecules  
- Upcoming trials  
*Y Allanore (F)*

17.25-17:55 **Session 7 - Treatment and DMARDS in SSc**  
Chairpersons: P Sampaio Barros (BRA), M Kuwana (JPN)

How to treat rapidly progressive SSc  
*C Denton (UK)*

16:55–18:15 **Session 8 – PARALLEL SESSION  Mechanism of fibrosis**  
Chairpersons: A Gabrielli (I), R Lafyatis (USA)

16:55 Biomechanical Signaling of Myofibroblast Activation  
*V Thannickal (USA)*

17:15 SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 (STAT3) REGULATES TRANSFORMING GROWTH FACTOR-BETA INDUCED FIBROSIS IN SYSTEMIC SCLEROSIS  
*B Sumova et al (D)*

17:25 INVESTIGATING THE ROLE OF MYOCARDIN RELATED TRANSCRIPTION FACTOR (MRTF) IN SYSTEMIC SCLEROSIS (SSC)  
*X Shiwen et al (UK)*

17:35 EPHRIN B2 IS OVEREXPRESSED IN HUMAN SCLERODERMA SKIN AND MEDIATES FIBROBLAST TO MYOFIBROBLAST DIFFERENTIATION AND INDUCES FIBROSIS IN MICE  
*M Kapoor et al (CAN)*

17:45 EXPERIMENTAL RENAL INJURY IN A TGF-beta DEPENDENT MOUSE MODEL OF SCLERODERMA  
*E Derrett-Smith et al (UK)*

17:55 DIRECT THROMBIN INHIBITOR DABIGATRAN ETIXILATE PROTECTS ALVEOLAR EPITHELIAL CELLS FROM APOPTOSIS IN A BLEOMYCIN MODEL OF SCLERODERMA-ASSOCIATED INTERSTITIAL LUNG DISEASE  
*G Bogatkevich et al (USA)*

18:05 STIMULATION OF THE SOLUBLE GUANYLATE CYCLASE (SGC) INHIBITS DERMAL FIBROSIS BY BLOCKING NON-CANONICAL TGF-BETA-SIGNALING  
*C Beyer et al (D)*
Saturday, February 8

08:00-09:00  **Session 9 – Meet the Professors session**
- Approach to SSc-Related Cardiac Disease
  *L Czirjak* (H) & *Y Allanore* (F)
- Approach to Kidney Management
  *L Guillevin* (F) & *C. Denton* (UK)
- Approach to Ulcer Therapy
  *M Vonk* (NL) & *S Guiducci* (I)
- Approach to Therapy of Tendon & Joint Inflammation
  *M Mayes* (USA)
- Approach to GI management
  *M Fox* (CH)

09:00–09:40  **Session 10 - Cardiovascular involvement**
  Chairpersons: *M Inanc* (TR), *A Vacca* (I)

09:00  Conduction and Rhythm defects in scleroderma
  *C Meune* (F)

09:20  IMPROVEMENT OF DIGITAL ULCERATIVE DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS IS ASSOCIATED WITH BETTER FUNCTIONAL PROGNOSIS
  *L Mouthon et al* (F)

09:30  PREDICTION OF CARDIAC AND VASCULAR EVENTS IN SYSTEMIC SCLEROSIS: INPUT FROM ENDOTHELIN-1 TYPE A RECEPTOR ANTIBODIES
  *J Avouac et al* (F)

9:40–10:30  **Session 11 - Interstitial lung disease**
  Chairpersons: *M Hudson* (CAN), *O Kowal Bielecka* (PL)

09:40  SSc-ILD: Who to treat and how to treat?
  - Discuss natural history and disease progression in ILD
  - How to identify patients who require immunosuppressive therapy
  - Efficient drugs and predictors of response
  *D Khanna* (USA)

10:00  PROGRESSIVE DETERIORATION OF PATIENTS WITH SCLERODERMA WITH PULMONARY INVOLVEMENT: 11-YEAR OUTCOMES FROM THE SCLERODERMA LUNG STUDY (SLS1)
  *K Sullivan et al* (USA)
Continued on Saturday, February 8

10:10 SURVIVAL AFTER LUNG TRANSPLANTATION IN SYSTEMIC SCLEROSIS. A SYSTEMATIC REVIEW
   S Johnson et al (CAN)

10:20 GENETIC MARKERS OF SUSCEPTIBILITY AND INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS
   PATIENTS: AN IMMUNOCHIP STUDY
   L Bossini-Castillo et al (E)

10:30-10:45 Coffee break

10:45-11:55 Session 12 - Pulmonary Arterial Hypertension
   Chairpersons: V Steen (USA), E Hachulla (F)

10:45 PAH: How to make the right diagnosis at the right time
   - Risk factors and predictors of PAH
   - Criteria guiding the clinician to refer the patient for catheterisation
   - How to interpret catheterisation
   O Distler (CH)

Chairpersons: M Hinchcliff (USA), L Chung (USA)

11:05 CHARACTERISTICS OF SYSTEMIC SCLEROSIS PATIENTS WITH PULMONARY HYPERTENSION AND A
   PULMONARY CAPILLARY WEDGE PRESSURE >15 IN THE PHAROS REGISTRY
   L Saketkoo et al (USA)

11:15 RECOMMENDATIONS FOR SCREENING AND DETECTION OF CONNECTIVE-TISSUE DISEASE
   ASSOCIATED PULMONARY ARTERIAL HYPERTENSION
   D Khanna et al (USA)

11:25 A COMPARISON OF THE PREDICTIVE ACCURACY OF THREE SCREENING MODELS (DETECT V. ESC/ERS
   V. ASIG) FOR PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC SCLEROSIS
   Y J Hao et al (AUS)

11:35 CLINICAL SUBTYPE AND AUTOANTIBODIES BOTH HELP PREDICT PULMONARY ARTERIAL
   HYPERTENSION BUT AUTOANTIBODIES ARE STRONGER PREDICTORS OF DEVELOPING SECONDARY
   PULMONARY HYPERTENSION
   R Domsic et al (USA)

11:45 PROGNOSTIC VALUE OF NT-ProBNP IN SYSTEMIC SCLEROSIS PATIENTS WITHOUT PULMONARY
   HYPERTENSION
   M Antivalle et al (I)

11:55-12.10 Special Lecture
   Chairpersons: F Del Galdo (UK), G Riemekasten (D)

   Desscipher, a jump in the future!
   U Mueller Ladner (D)
12:10-12:30  **Summary of the congress**  
Chairperson: L Guillemin (F)

Highlites of the World Scleroderma Congress, 2014  
*D Furst (USA)*

12:30-13:00  **Closing ceremony**